Free New data prompts CDC to examine adequacy of pre-op workup by gynecologists May 04, 2018Vol.44 No.18By Matthew Bin Han Ong
FreeTrials & Tribulations Learning to “talk less and smile more” while designing a COE strategy worthy of trust April 27, 2018Vol.44 No.17By Erin N. Kobetz
FreeTrials & Tribulations Sales Revenues at the Potential Expense of Patient Safety:The Example of You&i April 13, 2018Vol.44 No.15By Mark J. Ratain, Lisa S. Chen, Allen S. Lichter, R. Donald Harvey, Sonali M. Smith, Leonard B. Saltz, William G. Wierda, Varsha V. Gandhi and Michael J. Keating
FreeTrials & Tribulations The importance of staging lung cancer consistently and correctly worldwide April 06, 2018Vol.44 No.14By Fred R. Hirsch
Trials & Tribulations Rare Cancers, Common Need March 16, 2018Vol.44 No.11By Sandip Patel, Young Kwang Chae and Razelle Kurzrock
Conversation with The Cancer LetterFree BMS’s Farajallah: Opdivo is the only PD-1 inhibitor approved for four-week dosing March 09, 2018Vol.44 No.10By Matthew Bin Han Ong
FreeTrials & Tribulations A phase III trial seeks to determine whether diet and exercise can cure breast cancer March 02, 2018Vol.44 No.09By Jennifer A. Ligibel
FreeTrials & Tribulations Diversity within Diversity: Lessons from the Latinos of South Texas February 23, 2018Vol.44 No.08By Amelie G. Ramirez and Ruben A. Mesa
FreeTrials & Tribulations A Cancer Patient’s War on Cancer February 16, 2018Vol.44 No.07By C. Anthony "Tony" Blau
Trials & Tribulations Re: Drug Pricing My unsolicited advice to HHS Secretary Alex Azar February 02, 2018Vol.44 No.05By Patricia J. Goldsmith
